Parenteral Drugs (India) (NSE:PDPL) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 10, 2026)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) 5-Year Yield-on-Cost %?

Parenteral Drugs (India) NSE:PDPL 4 5-Year Yield-on-Cost % is 0.00 as of Jul. 10, 2026. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Parenteral Drugs (India)'s yield on cost for the quarter that ended in Mar. 2022 was 0.00.


The historical rank and industry rank for Parenteral Drugs (India)'s 5-Year Yield-on-Cost % or its related term are showing as below:



NSE:PDPL's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.24
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Parenteral Drugs (India)  (NSE:PDPL) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Parenteral Drugs (India) 5-Year Yield-on-Cost % Related Terms

NSE:PDPL vs ZTS, CTLT, VTRS: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parenteral Drugs (India)'s 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parenteral Drugs (India) 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parenteral Drugs (India)'s 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Parenteral Drugs (India)'s 5-Year Yield-on-Cost % falls into.


NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Parenteral Drugs (India) is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Parenteral Drugs (India) (NSE:PDPL) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 10, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s 5-Year Yield-on-Cost % too high?
Parenteral Drugs (India)'s current 5-Year Yield-on-Cost % is 0.00. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s 5-Year Yield-on-Cost % compare to ZTS and CTLT?
Parenteral Drugs (India)'s 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median 5-Year Yield-on-Cost % is 2.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.24, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Parenteral Drugs (India) and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parenteral Drugs (India)'s current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price